Lost in translation: animal models and clinical trials in cancer treatment.
暂无分享,去创建一个
M. Ghert | I. Mak | N. Evaniew
[1] V. Apostolopoulos. Cancer vaccines: looking to the future , 2013, Expert review of vaccines.
[2] K. Nathanson,et al. Immunotherapy at Large: The road to personalized cancer vaccines , 2013, Nature Medicine.
[3] A. Aruga,et al. Immunological monitoring of anticancer vaccines in clinical trials , 2013, Oncoimmunology.
[4] David Beare,et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma , 2013, Nature Genetics.
[5] T. Miyakawa,et al. Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .
[6] J. Olson,et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model , 2012, Proceedings of the National Academy of Sciences.
[7] Natalie Cook,et al. Predictive in vivo animal models and translation to clinical trials. , 2012, Drug discovery today.
[8] Heidi Ledford,et al. Translational research: 4 ways to fix the clinical trial , 2011, Nature.
[9] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[10] Raouf Khalil,et al. Faculty of 1000 evaluation for Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. , 2010 .
[11] H. Attarwala,et al. TGN1412: From Discovery to Disaster , 2010, Journal of young pharmacists : JYP.
[12] J. Bailar,et al. Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[13] P. Ferdinandy,et al. Matrix Metalloproteinase Inhibitors , 2010, Drugs.
[14] D. Howells,et al. Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy , 2010, PLoS biology.
[15] G. Curt,et al. One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis? , 2008, The oncologist.
[16] R. Matthews,et al. Medical progress depends on animal models - doesn't it? , 2008, Journal of the Royal Society of Medicine.
[17] J. Schellens,et al. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials , 2007, British Journal of Cancer.
[18] P. Sandercock,et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.
[19] Nicki Panoskaltsis,et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.
[20] C. Overall,et al. Towards third generation matrix metalloproteinase inhibitors for cancer therapy , 2006, British Journal of Cancer.
[21] JoAnn C L Schuh,et al. Trials, Tribulations, and Trends in Tumor Modeling in Mice , 2004, Toxicologic pathology.
[22] Elissa J Chesler,et al. Identification and ranking of genetic and laboratory environment factors influencing a behavioral trait, thermal nociception, via computational analysis of a large data archive , 2002, Neuroscience & Biobehavioral Reviews.
[23] Steven K. Gibb. Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.
[24] B. Fingleton,et al. Matrix metalloproteinases as valid clinical targets. , 2007, Current pharmaceutical design.
[25] S. H. van der Burg,et al. Vaccination for treatment and prevention of cancer in animal models. , 2006, Advances in immunology.
[26] Luna,et al. Translation of Research Evidence From Animals to Humans , 2006 .
[27] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .